In the pharmaceutical sector, quality is not an attribute added at the end of the project; It is a structural condition that must be integrated from the initial conception. Unlike other industrial sectors, where quality can be assessed primarily in terms of technical specifications or operational performance, in the pharmaceutical environment it also involves regulatory compliance, patient protection and sustainability of the business model.
Quality management in pharmaceutical projects is not limited to the final validation of the process or the documentary review prior to an inspection. Suppose design, execute and check each phase of the project under a systematic approach aligned with Good Manufacturing Practices (GMP), risk management principles and international quality systems standards.
The guides like I Q10 (Pharmaceutical Quality System), I Q9 (Quality Risk Management) y Feat of 5 have reinforced the concept of a life cycle-based approach, transferring responsibility for quality to all stages of the project: design, construction, installation, qualification and operation.
This first installment covers the fundamentals of quality, the importance of the regulatory framework and how to organize governance within a pharmaceutical project. The next installment will address risk management, document control, changes, deviations and integration with validation and suppliers.
Applicable regulatory and regulatory framework
Quality management in pharmaceutical projects is based on a clear and demanding regulatory framework. Among the main references are:
| ICH Q10 – Pharmaceutical Quality System | Establishes the pharmaceutical quality system model integrating development, technology transfer and commercial manufacturing. |
| ICH Q9 – Quality Risk Management | Defines the principles for the identification, analysis and control of risk associated with quality. |
| EU GMP (EudraLex Volume 4) | Establishes the requirements for Good Manufacturing Practices in the European Union. |
| 21 CFR Parts 210/211 from the fda | They regulate the manufacturing of medicines in the United States. |
| GAMP 5 (2nd Edition) | It provides a structured framework for the validation of computerized systems under a life cycle approach. |
These references They should not be interpreted as independent requirements, but as interconnected elements that make up the project's quality assurance system.
Quality by Design applied to projects
In a pharmaceutical project (for example, a new plant, a capacity expansion, the implementation of an aseptic line or a computerized GxP system) quality translates into system capacity to:
- Achieve consistently with product specifications.
- Guarantee the integrity of the data.
- Operate within controlled parameters.
- Be defensible before audits and regulatory inspections.
Quality management in projects does not only consist of generating documentation, but rather building objective evidence that the system is correctly designed, executed and controlled.
Quality governance in pharmaceutical projects
Rol de Quality Assurance (QA)
One of the most relevant strategic decisions is define the role of QA within the project. Organizations with greater regulatory maturity integrate QA from the conceptual phase, not only in the final approval of protocols.
The QA role includes:
- URS review and approval.
- Participation in risk analysis.
- Supervision of DQ, FAT and SAT.
- Approval of qualification protocols.
- Management of deviations and changes.
- Guarantee of documentary traceability.
Early QA involvement reduces regulatory risks and avoids later rework.
Organizational structure and responsibilities
In a pharmaceutical project, the organizational structure is not a secondary administrative element, but a critical component of the quality system. The way in which responsibilities are distributed, decisions are made, and approvals are documented directly determines the technical soundness of the project and its regulatory defensibility. Poorly defined governance not only generates operational inefficiencies, but also increases the risk of GMP deviations, uncontrolled changes and inspection findings.
Clear definition from the beginning
From the beginning of the project, a clear architecture of responsibilities must be established. This involves defining:
- who leads technically,
- who manages the schedule,
- who evaluates the impact on quality and
- who has final authority to approve critical decisions.
In regulated environments, it is not enough for functions to be implicit; They must be formally assigned and documented.
Functional independence of Quality Assurance
One of the fundamental principles is the functional independence of Quality Assurance (QA). Although the project is driven by Engineering or Project Management, decisions with an impact on quality cannot be left exclusively to technical or operational criteria.
Engineering can design solutions and propose alternatives; Project Management can prioritize resources and deadlines; but QA must evaluate the GMP impact and formally approve those decisions that affect regulatory requirements, validation or process control. This separation does not seek to generate bureaucracy, but protect the objectivity of the system against schedule or cost pressures.
Assignment of responsibilities through RACI model
To avoid ambiguities, it is highly recommended define a RACI model specific to the project. It is not enough to assign generic responsibilities by department; Each critical activity must have clearly identified its person responsible for execution, its ultimate person responsible for approval, and the functions that must be consulted or informed. Especially in activities such as URS approval, design reviews, FAT/SAT execution, deviation management and change control.
When this definition does not exist, delays appear due to duplicate reviews, blocked decisions or, in the worst case, informal approvals that lack documentary support.
Multidisciplinary participation in the project
Quality management in pharmaceutical projects is necessarily transversal. Production, Maintenance, Automation, IT, Regulatory Affairs and Validation must be involved from early phases. If these areas are incorporated only in final stages, it is common for technical incompatibilities, operational limitations O regulatory deficiencies that force late redesigns.
A mature organizational structure incorporates multidisciplinary review forums in conceptual and design phases, where critical decisions are evaluated before being consolidated.
Supplier management and supervision
The relationship with suppliers deserves specific treatment. In regulated projects, the supplier is not a mere contractor, but an extension of the quality system of the owner.
Therefore, the organizational structure must clearly define who technically supervises the supplier, who reviews and approves externally generated documentation, and how deviations detected in FAT or during installation are managed. Furthermore, contracts must explicitly reflect applicable GMP requirements, las documentary obligations and the Acceptance criteria.
The absence of this formal framework often results in inconsistent documentation or lack of traceability.
Decision escalation and incident management
Another critical aspect is decision escalation. Not all incidents require intervention at the same hierarchical level, but The organization must provide mechanisms formalities to escalate situations with significant impact on quality or compliance.
When critical deviations, design changes with GMP impact, or conflicts between deadline and regulatory compliance are detected, there must be a defined forum (for example, a project quality committee) with the authority to make strategic decisions and document them appropriately. The absence of these mechanisms leads to isolated decisions that are difficult to defend against audits.
Documentary evidence and regulatory defensibility
From a regulatory perspective, the organizational structure must be demonstrable. During inspections, authorities not only evaluate the technical outcome of the project, but also the governance that supported it. Therefore, evidence such as project organization charts, formal role descriptions, applicable procedures and approval records must exist. The traceability who decided that, when and under what justification It is part of the quality system.
Consequences of weak governance and benefits of a strong structure
When the organizational structure is weak, repetitive patterns are observed: changes implemented without formal evaluation, deviations closed without adequate impact analysis, diffuse responsibilities during audits or delays due to lack of internal alignment. These problems are rarely perceived in early stages, but emerge strongly during qualification or regulatory inspection.
On the contrary, clear governance provides tangible competitive advantages. Among them stand out:
- Reduction of rework and late modifications.
- Greater documentary coherence.
- Better alignment between quality and operation.
- More agile and defensible decision making.
- Less exposure to regulatory observations.
In this first installment we have established the foundations of quality management in pharmaceutical projects. We have seen that:
- Quality is not a final addition, but a structural element from the conception of the project.
- Regulatory compliance and international guidelines (ICH Q9, Q10, GAMP 5, EU GMP, FDA 21 CFR) provide the essential regulatory framework.
- Project governance, including early integration of QA and a clear organizational structure, is critical to reduce risks, ensure traceability and guarantee defensibility against audits.
The next installment will explore how to apply these bases in practice: risk management, documentary control, changes, deviations, integration with supplier qualification and supervision, tools that allow project quality to be taken from theory to operational execution.
Do you want to strengthen QA governance and integration in your next pharmaceutical project?
Our team can help you define clear organizational structures, critical roles and regulatory strategies from the conceptual phase. Contact us to evaluate how your project can integrate quality from the beginning.